Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis

• Market Cap: C$607.62M
• Dividend Yield: N/A
• Average Volume (3M): 53.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 33
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 61,503,180
• 10 Day Avg. Volume: 45,847
• 30 Day Avg. Volume: 53,430
• PEG Ratio: -0.19
• Price to Book (P/B): 3.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$20.60
• Price Target Upside: 110.42% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.94
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$10.00 ▲(2.15% Upside)
• Action: Reiterated Date: 03/15/26
• Date: Action: Reiterated 03/15/26

The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.

Positive Factors

Proprietary DiffuSphere platform

Eupraxia's DiffuSphere platform is a durable competitive asset enabling localized drug delivery. Platform-level differentiation can reduce systemic side effects and be applied across chronic indications (BPH, oncology), improving long-term commercial optionality and licensing/partnering prospects.

Strong post-financing balance sheet

Material equity build and minimal debt materially lower near-term solvency risk and increase financial flexibility. A stronger balance sheet supports sustained clinical development without immediate borrowing, reducing refinancing pressure and enabling strategic decision-making over months.

Recent public offering activity

Active prospectus filing and underwriter engagement represent a structural capital-raising capability. Access to public markets and executed offerings improve runway to advance EP-104GI and other programs, lowering short-term liquidity risk and supporting multi-stage clinical plans.

Negative Factors

Pre-revenue model with widening losses

Being pre-revenue with rapidly widening net losses makes long-term value highly contingent on clinical success and commercialization. Persistent negative profitability limits internal funding sources, increases reliance on external capital, and raises execution risk across 2–6 month horizons.

Worsening cash burn

Deepening negative operating and free cash flow signals ongoing funding needs. Continued cash burn forces recurrent financings that can dilute shareholders or constrain R&D pacing, creating structural risk to program continuity if market access to capital tightens.

Historical balance sheet volatility

Past swings to negative equity and elevated leverage highlight dependence on financing cycles. Even with current strength, this history implies a non-trivial probability of future dilution or leverage under stress, raising medium-term financial and execution uncertainty.

Eupraxia Pharmaceuticals Business Overview & Revenue Model

Company Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

How the Company Makes Money

null

Eupraxia Pharmaceuticals Financial Statement Overview

Summary

Development-stage profile with no revenue, widening losses (net income deteriorating to about -$53.9M in 2025), and worsening cash burn (operating cash flow about -$39.9M in 2025). Partially offset by a much stronger balance sheet with materially higher equity (~$112.5M in 2025) and minimal debt (~$0.2M), improving near-term solvency.

Income Statement

The company remains pre-revenue (total revenue is 0 across all provided annual periods), which is common in biotechnology but keeps the income statement profile weak. Losses have widened meaningfully, with net income declining from about -$4.0M (2020) to roughly -$53.9M (2025), alongside deeply negative EBIT/EBITDA. A positive is that the business has been able to fund R&D/operations to progress the pipeline, but the current trajectory reflects heavy operating spend without offsetting commercialization revenue, leaving profitability highly dependent on future clinical and financing outcomes.

Balance Sheet

Balance sheet strength improved sharply versus earlier years: stockholders’ equity rose from ~$2.2M (2023) to ~$33.4M (2024) and ~$112.5M (2025), with total assets increasing to ~$118.1M (2025). Leverage is currently very low (total debt ~$0.2M in 2025 and ~$0.1M in 2024), reducing solvency risk in the near term. The main weakness is that returns remain deeply negative due to ongoing losses, and historical volatility is notable (including negative equity in 2020 and elevated leverage in 2023), implying the balance sheet can swing materially based on financing cycles.

Cash Flow

Cash generation is negative and worsening: operating cash flow was about -$14.6M (2021), -$18.8M (2022), -$27.9M (2023), -$30.0M (2024), and -$39.9M (2025), with free cash flow similarly negative (around -$40.7M in 2025). The recent positive free cash flow growth in 2025 reflects a less-negative change versus 2024 rather than true cash profitability, and the company remains reliant on external funding to sustain operations. A modest positive is that cash burn appears broadly aligned with reported losses in several years (free cash flow roughly tracking net loss in 2021–2024), suggesting losses are not being materially understated by cash items.

Breakdown	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-332.16K	-235.25K	-209.91K	-193.27K	-111.53K
EBITDA	-53.37M	-33.72M	-37.40M	-22.14M	-21.96M
Net Income	-53.90M	-34.94M	-37.39M	-23.26M	-22.99M
Balance Sheet
Total Assets	118.09M	50.24M	26.72M	25.88M	31.22M
Cash, Cash Equivalents and Short-Term Investments	110.43M	33.10M	19.34M	24.74M	29.90M
Total Debt	211.59K	103.31K	10.45M	10.55M	9.49M
Total Liabilities	7.82M	4.46M	25.55M	14.51M	11.67M
Stockholders Equity	112.46M	33.40M	2.22M	12.86M	20.39M
Cash Flow
Free Cash Flow	-40.72M	-30.10M	-28.02M	-19.08M	-15.07M
Operating Cash Flow	-39.90M	-29.99M	-27.92M	-18.78M	-14.64M
Investing Cash Flow	-822.93K	-75.16K	-99.03K	8.70M	-14.45M
Financing Cash Flow	106.28M	45.78M	27.84M	13.52M	49.92M

Eupraxia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Negative. The current price of 9.79 is below the 20-day moving average (MA) of 10.73, below the 50-day MA of 11.32, and above the 200-day MA of 8.73, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 35.74 is Neutral, neither overbought nor oversold. The STOCH value of 29.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:EPRX.

Eupraxia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EPRX	49 Neutral	C$607.62M	-7.65	-59.46%	―	―	―
ENBI	47 Neutral	C$1.39M	-6.62	-107.76%	―	―	34.22%
DRUG	44 Neutral	C$979.01M	-28.32	-30.79%	―	―	-43.64%

Eupraxia Pharmaceuticals Corporate Events

Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing

Eupraxia Pharmaceuticals reported a wider fourth-quarter 2025 net loss of $16.7 million, compared with $7.5 million a year earlier, as it ramped research and development spending on its lead EP-104GI program and expanded general and administrative costs. The company ended 2025 with $80.5 million in cash, bolstered by recent financings including a February 2026 equity and pre-funded warrant offering that raised about $63.2 million, which it expects will fund operations into the second half of 2028.

Operationally, Eupraxia highlighted additional 52-week follow-up data and positive biopsy-based tissue health results from its RESOLVE trial in eosinophilic esophagitis, supporting the potential of EP-104GI and setting up multiple clinical readouts in 2026. Management is also monitoring evolving U.S.-Canada tariff dynamics due to its U.S.-based manufacturing arrangements, assessing potential direct and indirect impacts on its supply chain while maintaining U.S. dollar balances to manage currency and trade-related risks.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.

Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline

Eupraxia Pharmaceuticals has priced a public offering of approximately US$55 million in common shares and pre-funded warrants, with an additional 30-day option for underwriters to buy more shares, and expects the transaction to close on February 20, 2026, pending customary approvals from the Toronto Stock Exchange and Nasdaq. The company plans to deploy the proceeds to advance EP-104GI through preclinical work, Phase 2 and Phase 3 preparations, expand studies into additional gastrointestinal indications such as esophageal strictures and fibrostenotic Crohn’s disease, and fund broader R&D, business development, intellectual property, and corporate infrastructure to support future growth.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.

Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline

Eupraxia Pharmaceuticals has filed a preliminary prospectus supplement to launch a proposed public offering of common shares, or pre-funded warrants, in Canada and the U.S., with Cantor and LifeSci Capital as joint bookrunners and Bloom Burton as co-manager. The size, pricing and timing remain subject to market conditions, regulatory approvals, and stock exchange listing requirements.

The company plans to deploy the net proceeds to advance its EP-104GI program for Eosinophilic Esophagitis through Phase 2 and Phase 3 preparation, expand studies into other gastrointestinal indications such as esophageal strictures and fibrostenotic Crohn’s disease, and fund additional R&D, business development, and corporate infrastructure. The financing aims to accelerate Eupraxia’s late-stage pipeline and commercial readiness, potentially strengthening its position in the GI-focused biotech space and supporting future growth initiatives.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.

Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI

Eupraxia Pharmaceuticals reported encouraging interim results from the Phase 1b/2a portion of its RESOLVE trial of EP-104GI in eosinophilic esophagitis, showing near-complete normalization of esophageal tissue health at the highest dose by week 12 and sustained improvements at lower doses out to week 36. A majority of patients who had at least 60% of their esophagus treated achieved and maintained clinical remission for up to 52 weeks after a single administration, with more than 200 patient-months of follow-up showing no serious adverse events or oral candidiasis, bolstering EP-104GI’s profile as a potentially once-yearly treatment and supporting ongoing recruitment in the randomized Phase 2b trial, with top-line data expected in 2026.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.